Disc Medicine (IRON) is back in focus after the FDA issued a Complete Response Letter for its bitopertin program, triggering a 22% one day share price drop and a shareholder rights investigation.

Beyond the sharp reaction to the FDA Complete Response Letter and the shareholder rights investigation, Disc Medicine’s recent 7 day share price return of 8.47% and 30 day share price return of 8.02% sit alongside a 90 day share price return of 17.59% and a 1 year total shareholder return of 58.13%. Taken together, these figures highlight strong longer term gains despite fading shorter term momentum.

If this kind of regulatory and clinical headline has your attention, it might be a good moment to scan other potential ideas using our screener of 36 healthcare AI stocks

With Disc Medicine now trading at US$65.18, alongside a reported intrinsic discount of about 50% and a value score of 3, investors have to ask whether this reflects a genuine mispricing or whether the market is already factoring in expectations for future growth.

Price to Book of 3.4x: Is it justified?

At around $65.18, Disc Medicine trades on a P/B of 3.4x, which screens as expensive against the broader US biotechs P/B average of 2.3x.

The P/B ratio compares the market value of the company to its book value, which is effectively the net assets on the balance sheet. For a clinical stage biotech with minimal revenue and ongoing losses, investors often focus on P/B because earnings based metrics like P/E are not meaningful.

Here the picture is mixed. The shares are described as trading at roughly a 50.3% discount to an estimate of fair value based on the SWS DCF model. However, the 3.4x P/B multiple is higher than the 2.3x industry average and still lower than a 6.2x peer group average. That suggests the market is assigning a premium to Disc Medicine against the wider biotech group, while pricing it below closer peers that may share similar characteristics.

Compared with the US biotechs industry at 2.3x, the 3.4x P/B stands out as meaningfully higher, while still looking comparatively modest next to the 6.2x peer average. That contrast points to a valuation that sits between broad sector pricing and more specialised comparables.

Result: Price to book ratio of 3.4x (ABOUT RIGHT)

However, investors still face clear risks, including future FDA decisions on bitopertin and the company’s current position of zero revenue alongside a US$212.184 million net loss.

Another View: DCF Points to a Different Story

While the 3.4x P/B suggests Disc Medicine is priced at a premium to the broader biotech group, the SWS DCF model tells a different story. With an estimated future cash flow value of $131.23 per share versus the current $65.18 price, the stock screens as materially undervalued. This raises the question of which signal should carry more weight for investors at this time.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Disc Medicine for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 59 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does this mix of pressure and potential match how you see Disc Medicine right now, and are you comfortable with that balance? To move quickly from headline reaction to your own evidence based view, check out the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If Disc Medicine is already on your radar, do not stop there. Use this moment to line up a few more watchlist candidates that fit your style.

• Target long term compounding potential by searching for quality companies trading below their estimated worth with the 59 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses that pair financial strength with staying power using the 68 resilient stocks with low risk scores.
• Get ahead of the crowd by hunting for quality names that have not yet drawn heavy attention via the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.